Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice

Gregory T. Wurz, Karla C. Read, Cristina Marchisano-Karpman, Jeffrey Gregg, Laurel A Beckett, Qilu Yu, Michael W. DeGregorio

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Ospemifene is a new selective estrogen receptor modulator (SERM) that is being developed for the treatment of urogenital atrophy and osteoporosis. Similarly to other SERMs, ospemifene exhibits antiestrogenic effects in breast tissue, which led to the hypothesis that it may be a potential breast cancer chemopreventive agent. We first assessed the ability of ospemifene, compared to tamoxifen and raloxifene, to prevent dimethylbenzanthracene (DMBA)-induced mammary tumors in female Sencar mice. Ospemifene (N = 18), tamoxifen (N = 20) and raloxifene (N = 17), each dosed at 50 mg/kg, were administered daily by oral gavage, in combination with 20 μg DMBA for the first 6 weeks. Control mice (N = 21) received vehicle plus DMBA only for the first 6 weeks. Daily treatment then continued for 37 weeks. As hypothesized, ospemifene greatly reduced the incidence of mammary carcinomas compared to control mice (p = 0.003), similar to tamoxifen (p = 0.0004); however, in the raloxifene group, no significant effect was seen in mammary tumor prevention (p = 0.20). A follow-up study comparing ospemifene (N = 20) to tamoxifen (N = 20) in the same model was then performed to confirm the results of the first study. The results of the follow-up study, which extended the treatment to 52 weeks, confirmed the results of our previous study, with ospemifene (p = 0.01) and tamoxifen (p = 0.004) significantly decreasing mammary carcinomas compared to controls. The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects.

Original languageEnglish (US)
Pages (from-to)230-240
Number of pages11
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume97
Issue number3
DOIs
StatePublished - Nov 2005

Fingerprint

Tumors
Breast Neoplasms
Tamoxifen
Growth
Selective Estrogen Receptor Modulators
Osteoporosis
Atrophy
Ospemifene
Breast
Tissue
Incidence
Therapeutics
Raloxifene Hydrochloride

Keywords

  • Breast cancer
  • Chemoprevention
  • DMBA
  • Ospemifene
  • SERM

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. / Wurz, Gregory T.; Read, Karla C.; Marchisano-Karpman, Cristina; Gregg, Jeffrey; Beckett, Laurel A; Yu, Qilu; DeGregorio, Michael W.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 97, No. 3, 11.2005, p. 230-240.

Research output: Contribution to journalArticle

Wurz, Gregory T. ; Read, Karla C. ; Marchisano-Karpman, Cristina ; Gregg, Jeffrey ; Beckett, Laurel A ; Yu, Qilu ; DeGregorio, Michael W. / Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. In: Journal of Steroid Biochemistry and Molecular Biology. 2005 ; Vol. 97, No. 3. pp. 230-240.
@article{00a2d705d33c43efa4b261f097937e3f,
title = "Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice",
abstract = "Ospemifene is a new selective estrogen receptor modulator (SERM) that is being developed for the treatment of urogenital atrophy and osteoporosis. Similarly to other SERMs, ospemifene exhibits antiestrogenic effects in breast tissue, which led to the hypothesis that it may be a potential breast cancer chemopreventive agent. We first assessed the ability of ospemifene, compared to tamoxifen and raloxifene, to prevent dimethylbenzanthracene (DMBA)-induced mammary tumors in female Sencar mice. Ospemifene (N = 18), tamoxifen (N = 20) and raloxifene (N = 17), each dosed at 50 mg/kg, were administered daily by oral gavage, in combination with 20 μg DMBA for the first 6 weeks. Control mice (N = 21) received vehicle plus DMBA only for the first 6 weeks. Daily treatment then continued for 37 weeks. As hypothesized, ospemifene greatly reduced the incidence of mammary carcinomas compared to control mice (p = 0.003), similar to tamoxifen (p = 0.0004); however, in the raloxifene group, no significant effect was seen in mammary tumor prevention (p = 0.20). A follow-up study comparing ospemifene (N = 20) to tamoxifen (N = 20) in the same model was then performed to confirm the results of the first study. The results of the follow-up study, which extended the treatment to 52 weeks, confirmed the results of our previous study, with ospemifene (p = 0.01) and tamoxifen (p = 0.004) significantly decreasing mammary carcinomas compared to controls. The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects.",
keywords = "Breast cancer, Chemoprevention, DMBA, Ospemifene, SERM",
author = "Wurz, {Gregory T.} and Read, {Karla C.} and Cristina Marchisano-Karpman and Jeffrey Gregg and Beckett, {Laurel A} and Qilu Yu and DeGregorio, {Michael W.}",
year = "2005",
month = "11",
doi = "10.1016/j.jsbmb.2005.06.027",
language = "English (US)",
volume = "97",
pages = "230--240",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice

AU - Wurz, Gregory T.

AU - Read, Karla C.

AU - Marchisano-Karpman, Cristina

AU - Gregg, Jeffrey

AU - Beckett, Laurel A

AU - Yu, Qilu

AU - DeGregorio, Michael W.

PY - 2005/11

Y1 - 2005/11

N2 - Ospemifene is a new selective estrogen receptor modulator (SERM) that is being developed for the treatment of urogenital atrophy and osteoporosis. Similarly to other SERMs, ospemifene exhibits antiestrogenic effects in breast tissue, which led to the hypothesis that it may be a potential breast cancer chemopreventive agent. We first assessed the ability of ospemifene, compared to tamoxifen and raloxifene, to prevent dimethylbenzanthracene (DMBA)-induced mammary tumors in female Sencar mice. Ospemifene (N = 18), tamoxifen (N = 20) and raloxifene (N = 17), each dosed at 50 mg/kg, were administered daily by oral gavage, in combination with 20 μg DMBA for the first 6 weeks. Control mice (N = 21) received vehicle plus DMBA only for the first 6 weeks. Daily treatment then continued for 37 weeks. As hypothesized, ospemifene greatly reduced the incidence of mammary carcinomas compared to control mice (p = 0.003), similar to tamoxifen (p = 0.0004); however, in the raloxifene group, no significant effect was seen in mammary tumor prevention (p = 0.20). A follow-up study comparing ospemifene (N = 20) to tamoxifen (N = 20) in the same model was then performed to confirm the results of the first study. The results of the follow-up study, which extended the treatment to 52 weeks, confirmed the results of our previous study, with ospemifene (p = 0.01) and tamoxifen (p = 0.004) significantly decreasing mammary carcinomas compared to controls. The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects.

AB - Ospemifene is a new selective estrogen receptor modulator (SERM) that is being developed for the treatment of urogenital atrophy and osteoporosis. Similarly to other SERMs, ospemifene exhibits antiestrogenic effects in breast tissue, which led to the hypothesis that it may be a potential breast cancer chemopreventive agent. We first assessed the ability of ospemifene, compared to tamoxifen and raloxifene, to prevent dimethylbenzanthracene (DMBA)-induced mammary tumors in female Sencar mice. Ospemifene (N = 18), tamoxifen (N = 20) and raloxifene (N = 17), each dosed at 50 mg/kg, were administered daily by oral gavage, in combination with 20 μg DMBA for the first 6 weeks. Control mice (N = 21) received vehicle plus DMBA only for the first 6 weeks. Daily treatment then continued for 37 weeks. As hypothesized, ospemifene greatly reduced the incidence of mammary carcinomas compared to control mice (p = 0.003), similar to tamoxifen (p = 0.0004); however, in the raloxifene group, no significant effect was seen in mammary tumor prevention (p = 0.20). A follow-up study comparing ospemifene (N = 20) to tamoxifen (N = 20) in the same model was then performed to confirm the results of the first study. The results of the follow-up study, which extended the treatment to 52 weeks, confirmed the results of our previous study, with ospemifene (p = 0.01) and tamoxifen (p = 0.004) significantly decreasing mammary carcinomas compared to controls. The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects.

KW - Breast cancer

KW - Chemoprevention

KW - DMBA

KW - Ospemifene

KW - SERM

UR - http://www.scopus.com/inward/record.url?scp=27744590563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744590563&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2005.06.027

DO - 10.1016/j.jsbmb.2005.06.027

M3 - Article

C2 - 16153821

AN - SCOPUS:27744590563

VL - 97

SP - 230

EP - 240

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 3

ER -